• Miscellaneous dermatological conditions

Varithena Generic Name & Formulations

General Description

Polidocanol 1% (1.3mg/mL); foam for IV inj after activation.

Pharmacological Class

Sclerosing agent.

How Supplied

Convenience box—1 (w. canisters, transfer units, administration boxes); Bi-canister—1; Administration pack—1 (transfer unit, components)


Generic Availability


Varithena Indications


Treatment of incompetent great saphenous veins (GSV), accessory saphenous veins, and visible varicosities of the great saphenous vein system above and below the knee.

Varithena Dosage and Administration


See full labeling. For IV inj using ultrasound guidance, administered via a single cannula into the lumen of the target incompetent trunk veins or by direct inj into varicosities. Inject foam slowly (approx. 1mL/sec in the GSV and 0.5mL/sec in accessory veins or varicosities). Give up to 5mL per inj; max 15mL per treatment session. Repeat if necessary; separate sessions by a minimum of 5 days. Apply compression bandage or stocking. Have the patient walk for at least 10mins after treatment; monitor. Maintain compression for 2 weeks post-treatment.


Not established.

Varithena Contraindications


Acute thromboembolic diseases.

Varithena Boxed Warnings

Not Applicable

Varithena Warnings/Precautions


Do not inject intra-arterially. Must be experienced in venous procedures. Monitor for at least 10mins post-inj for anaphylaxis; treat appropriately if occurs. Increased risk of tissue ischemia in peripheral arteriosclerosis or thromboangiitis obliterans (Buerger’s Disease). Monitor for venous thrombosis post-treatment. Increased risk of thrombosis in patients with reduced mobility, history of DVT/PE, pregnancy, major surgery within 3mos, prolonged hospitalization. Pregnancy. Nursing mothers: consider interrupting breastfeeding up to 8hrs after dose.

Varithena Pharmacokinetics

See Literature

Varithena Interactions

Varithena Adverse Reactions

Adverse Reactions

Pain/discomfort in extremity, infusion site thrombosis (retained coagulum), inj site hematoma or pain, thrombophlebitis superficial, extravasation; anaphylaxis (may be fatal).

Varithena Clinical Trials

See Literature

Varithena Note

Not Applicable

Varithena Patient Counseling

See Literature